



Short communication

Increased serum levels of novel T cell cytokines IL-33, IL-9 and IL-17 in subjects with type-1 diabetes

Sugumar Shruthi ^a, Viswanathan Mohan ^b, Anandakumar Amutha ^b, Vivekanandhan Aravindhan ^{a,*}^a Dept of Genetics, Dr ALM PG IBMS, University of Madras, Taramani, Chennai, India^b Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialties Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, Chennai, India

ARTICLE INFO

Article history:

Received 27 March 2016

Received in revised form 24 June 2016

Accepted 9 July 2016

Available online 18 July 2016

Keywords:

IL-33

IL-17

IL-9

T cell cytokines

Type-1 diabetes

Adaptive cytokines

ABSTRACT

The role of adaptive immune cytokines in the pathogenesis of type-1 Diabetes Mellitus (T1DM) is well known. Even though reports on the serum levels of both Th-1 and Th-2 cytokines are available, those on newly described T cell cytokines such as IL-17, IL-33 and IL-9 in T1DM are scarce. We therefore measured the serum levels of both T cell polarizing (IL-33 and IL-12) and T cell effector (IFN- γ , IL-4, IL-10, IL-17 and IL-9) cytokines in T1DM subjects with and without microvascular (retinopathy and nephropathy) complications (MVC). All the tested cytokines were significantly elevated in T1DM subjects except for IFN- γ (which failed to attain statistical significance) with no significant difference between those with and without MVC. From the serum cytokine analysis, no apparent Th polarization could be determined for the T1DM subjects.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Type-1 Diabetes Mellitus (T1DM) is an autoimmune disorder which arises due to immune mediated destruction of pancreatic β -cells [1]. Infiltration of T cells is widely believed to mediate this destruction and is facilitated by the secretion of cytokines [1]. Adaptive immune cytokines include both Th polarizing and T cell effector cytokines which together shape the adaptive arm of the immune response [2]. While the former is largely secreted by professional antigen presenting cells (APCs) and act on naïve T cells, the latter is predominantly secreted by polarized T cells and act on other immune/non-immune cells [2]. Earlier reports, including ours have shown significantly increased levels of pro-inflammatory cytokines like TNF- α , IL-6, IL-1 β and GM-CSF in T1DM subjects [3]. However, reports documenting the levels of adaptive immune cytokines in T1DM are scant. Recently, several novel T cells cytokines like IL-33, IL-17 and IL-9 have been described. While IL-12 has long been known as the master regulator of Th-1 polarization, IL-33 has recently emerged as a master regulator for Th-2 polarization [4]. IL-17 and IL-9 are secreted by the newly discovered Th17 and Th9 cells, which play an important role in neutrophil recruitment and mucosal immunity respectively

[5]. Even though, the involvement of these cytokines in T1DM has been implicated in animal models [6], a complete profile of adaptive immune cytokines including the recently described ones in T1DM is largely lacking. These cytokines play an important role both during early (beta cell loss) [1] and late (endothelial dysfunction) stages of the disease as shown in animal studies [1]. In the present study, we measured the serum levels of both T cell polarizing (IL-33 and IL-12) and T cell effector (IFN- γ , IL-4, IL-10, IL-17 and IL-9) cytokines in T1DM subjects with and without microvascular (retinopathy and nephropathy) complications.

2. Materials and methods

2.1. Study groups and sample size calculation

The control normal glucose tolerant group (NGT; n = 76) was obtained from the Chennai Urban Rural Epidemiological Study (CURES) [7]. Test groups include T1DM without microvascular complications (T1DM, n = 29) and T1DM with MVC (T1DM-MVC, n = 96) were obtained from our centre (2008–2010). Institutional Ethics Committee approval was obtained from the Madras Diabetes Research Foundation (Ref. No.MDRF-EC/SOC/2009/05) and written informed consent was obtained from all the study participants. The study was conducted as per principles of the declaration of Helsinki as revised in 2008. As a pilot study, cytokine levels were analyzed in 20 normal glucose tolerant (NGT) individuals, 20 T1DM

* Corresponding author at: Dept of Genetics, Dr ALM PG IBMS, University of Madras, Taramani, Chennai 600113, India.

E-mail addresses: cvaravindhan@gmail.com, cvaravindhan@yahoo.co.uk (V. Aravindhan).

subjects with MVC and 20 without MVC. The preliminary results obtained gave a sample size of 130 study subjects (50 NGT, 30 T1DM and 50 T1DM-MVC subjects) with p value <0.05, confidence interval of 95% and a power of 80%. We increased the sample size by 20–30% in the NGT and T1DM-MVC groups to account for the wide variation seen in serum cytokine levels.

2.2. Diagnosis of type-1 diabetes and microvascular complications

Diagnosis of T1DM was based on abrupt onset of diabetes, absence of pancreatic beta cell reserve (as shown by fasting and stimulated C-peptide levels <0.6 pmol/ml) and requiring insulin right from time of diagnosis [8]. The T1DM group with MVC included subjects with retinopathy (DR) (41.57%), nephropathy (DN) (n = 57.30%) and those with both (DN + DR) (n = 1.13%). Patients with gestational diabetes, type-2 diabetes, type-1 diabetes with macrovascular complications, renal diseases, chronic infections, liver cirrhosis, congestive heart failure and chronic lung disease were excluded. Diagnosis of microalbuminuria was performed based on albumin excretion as mentioned previously [7]. Retinopathy was diagnosed by the presence of at least one microaneurysm in the retinal photographs taken using a Zeiss retinal camera (Oberkochen, Germany). The photographs were studied according to the Early Treatment Diabetic Retinopathy study (ETDRS) criteria [7].

2.3. Anthropometric measurements and biochemical tests

Body mass index (BMI) was obtained using standard methods. Blood pressure was recorded using a sphygmomanometer (Deluxe BP apparatus; Diamond, Pune, India). Fasting plasma glucose was measured using hexokinase method, serum cholesterol by cholesterol oxidase–peroxidase–amidopyrine method, serum triglycerides by glycerol phosphate oxidase–peroxidase–amidopyrine method, high-density lipoprotein (HDL) cholesterol by direct method using polyethylene glycol-pretreated enzymes, and creatinine by Jaffe's method using a Hitachi- 912Autoanalyzer (Hitachi, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. Glycated hemoglobin (HbA1c), was measured by high pressure liquid chromatography (HPLC) (Bio-Rad, Hercules, CA).

2.4. Measurement of serum cytokine levels

The serum levels of IL-12 (Invitrogen, USA), IFN- γ (Invitrogen, USA), IL-4 (Invitrogen, USA), IL-33 (Biolegend, CA15-), IL-17 (PeproTech, USA) and IL-9 (ebiosciences, USA) were measured by sandwich ELISA following kit protocol. The lowest detection limits for the tested cytokines were: IL-12-1.95 pg/ml, IFN- γ -1.17 pg/ml, IL-10-9.76 pg/ml, IL-33-0.016 ng/ml, IL-4-1.9 pg/ml, IL-9-1.95 pg/ml and IL-17-0.02 ng/ml.

2.5. Statistical analysis

Data are expressed as mean values for biochemical parameters and geometric mean values for cytokines. One-way ANOVA was used to compare groups for continuous variables, whereas χ^2 test or Fisher exact test (as appropriate) was used to compare proportions. Kruskal-Wallis test was used for parameters which did not show normal distribution. Multiple comparisons were corrected using the Holm's correction for each set of analysis. All the analyses were done using SPSS statistical package (Version 20.0; SPSS, Chicago, IL) and p value less than 0.05 was considered significant.

3. Results and discussion

As shown in Table 1, a significant difference was found with respect to age across the groups, T1DM without MVC being significantly younger compared to control and TDM with MVC. BMI was significantly lower in T1DM subjects compared to the NGT group. Systolic and diastolic blood pressures were comparable between groups and were within the normal range. Total cholesterol, triglyceride lipids (TGL) and low-density lipoprotein cholesterol (LDL) were significantly lower, while the HDL levels were significantly higher in T1DM (both with and without MVC) subjects compared to NGT. Blood urea and microalbuminuria levels were significantly increased in T1DM with MVC compared to NGT and T1DM without MVC. All T1DM subjects were under insulin and anti-hypertensive drugs.

Serum IL-12 levels [Geometric mean (Range); p value] were significantly elevated in T1DM subjects with MVC [40.4(3.3–340.6) pg/ml; p < 0.001] and those without MVC [41.8(3.9–348.1) pg/ml; p < 0.001] when compared with NGT [10.89(3.3–52.0) pg/ml] (Fig. 1a). Serum IL-33 levels were also significantly elevated in T1DM subjects with MVC [0.27(0.01–10.5) ng/ml; p < 0.001] and those without MVC [0.35(0.02–10.3) ng/ml; p < 0.001] when compared with NGT [0.05(0.01–7.9) ng/ml] (Fig. 1b). Even though IFN- γ levels were slightly elevated in T1DM subjects with MVC [2.7(2.0–89.2) pg/ml] and without MVC [3.15(2.0–202.6) pg/ml] but it was not statistically significant when compared with NGT [2.5(2.08–13.8) pg/ml] (Fig. 1c). Serum IL-4 levels were significantly increased in T1DM subjects with MVC [7.22(3.7–738.1) pg/ml;

Table 1
Clinical characteristic of the study groups.

Clinical characteristics	NGT n = 76	T1DM n = 29	T1DM-MVC n = 96
Age (years)	32.0 ± 1.7	21.5 ± 11.0**	29.0 ± 15.2
Gender (F/M)	65/31	14/15	43/53
BMI (kg/m ²)	23.1 ± 4.3	20.3 ± 4.6*	20.3 ± 5.2**
Systolic BP (mm Hg)	114 ± 15.5	111.9 ± 14.9	113.5 ± 14.9
Diastolic BP (mm Hg)	72.8 ± 10.9	70.6 ± 7.1	72.5 ± 7.8
FPG (mg/dL)	85.9 ± 9.5	200.9 ± 110.5***	193.5 ± 104.7***
PPBS (mg/dL)	100.4 ± 18.2	251 ± 124.6***	272.8 ± 136.1***
HbA1c level (%)	5.4 ± 0.4	9.0 ± 2.3***	8.9 ± 1.9***
Serum cholesterol (mg/dL)	171.2 ± 33.0	156.8 ± 33.5	165.3 ± 36.2
Serum triglycerides (mg/dL)	114.3 ± 56.9	96.1 ± 43.5	84.2 ± 38.4***
HDL cholesterol (mg/dL)	43.1 ± 10.0	46.3 ± 11.0	48.6 ± 54.1***
LDL cholesterol (mg/dL)	102.1 ± 28.1	89.4 ± 28.3	95.5 ± 36.1
Blood urea (mg/ dL)	16.2 ± 2.1	15.9 ± 2.8	23.8 ± 7.1***
Microalbuminuria (mg/dL)	7.6 ± 5.4	6.8 ± 6.2	27.6 ± 49.7***
Disease duration ^a (years)	0	8.0 ± 6.0	13.1 ± 8.7
Treatment	0	Insulin and anti- hypertensive drugs	Insulin and anti- hypertensive drugs

FPS- Fasting Plasma Glucose; PPBS- Post Prandial Blood Sugar; MVC- Microvascular Complications; HbA1c- Glycated Hemoglobin; HDL- High Density Lipoprotein; LDL- Low Density Lipoprotein; NS- Non-Significant.

T1DM and T1DM-MVC groups were statistically compared with NGT using One-way ANOVA test on PRISM software. Data are mentioned above as mean ± SD for continuous variables and proportions are mentioned as percentage.

^a Comparison between T1DM and T1DM-MVC groups using Mann-Whitney test.

* <0.05.

** <0.01.

*** <0.001.

Download English Version:

<https://daneshyari.com/en/article/2793757>

Download Persian Version:

<https://daneshyari.com/article/2793757>

[Daneshyari.com](https://daneshyari.com)